

Special Commission to Study Switching Medications

Created pursuant to Section 195 of
Chapter 133 of the Acts of 2016

November 30, 2017
1:00 pm – 3:00 pm
6th floor, 100 Hancock St, Quincy

Minutes

Chair: Paul Jeffrey

Scribe: Nancy Schiff

Commission Members in Attendance: P Jeffrey, D Schiel (phone), C Griffin (phone), E Kiriakopoulos (phone), S Sadownik (phone), K. Krishnamurthy (phone); P Summergrad

Commission Members not in Attendance: L Stairs, D Mauch

Others in Attendance: N Schiff, D Cahill (BCB Government Relations, Inc.)

Meeting Summary:

1. The minutes from the October meeting were approved
2. The group discussed the status of the past month's action items and status of deliverables.
3. Analysis
 - a. Paul and Deb have been discussing what drugs to include in the analysis and reported their progress to the group.
 - b. The group made future suggestions for the final analysis based on what is feasible with the available data.
4. Literature review
 - a. The group discussed of the results of the literature to date.
 - b. If we find information about insurers who are also PBMs and how/if that impacts switching, it will be added to the literature review.
5. Surveys
 - a. The group reviewed the results of the patient survey
 - b. The Health Plan and Physician surveys still need to be analyzed. HPC will do this.
6. Listening Session
 - a. The group discussed the general themes that arose in the Listening Session.
 - b. These themes were similar to findings in the literature review and surveys.
7. Next steps
 - a. The group discussed how Commission members would submit their recommendations to the Chair for the report to the Legislature.

- b. Members decided it was fine to submit comments to include in the draft report and/or to make comments later.
- c. The Commission members will hold a closed session meeting to finalize the recommendation. The meeting will be on Thursday December 14 from 1-3 by conference call.

8. Adjournment

Respectfully Submitted,

A handwritten signature in black ink, reading "Paul L. Jeffrey". The signature is written in a cursive, flowing style.

Paul L. Jeffrey, PharmD

Materials Distributed at the Meeting:

Minutes from October meeting
Agenda
Summary of testimony from the Listening Session